CXCL11



CXCL11

F1FF1P2PP2M3MM3F4FF4K5KK5R6RR6G7GG7R8RR8C9CC9L10LL10C11CC11I12II12G13GG13P14PP14G15GG15V16VV16K17KK17A18AA18V19VV19K20KK20V21VV21A22AA22D23DD23I24II24E25EE25K26KK26A27AA27S28SS28I29II29M30MM30Y31YY31P32PP32S33SS33N34NN34N35NN35C36CC36D37DD37K38KK38I39II39E40EE40V41VV41I42II42I43II43T44TT44L45LL45K46KK46E47EE47... and 26 more residue(s)...... and 26 more residue(s)

SMILES None
InChIKey None
Sequence FPMFKRGRCLCIGPGVKAVKVADIEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKNF

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections

Structure pdb 8HNK
Ligand site mutations CXCR3


No bioactivity data available.

CXCL11

F1FF1P2PP2M3MM3F4FF4K5KK5R6RR6G7GG7R8RR8C9CC9L10LL10C11CC11I12II12G13GG13P14PP14G15GG15V16VV16K17KK17A18AA18V19VV19K20KK20V21VV21A22AA22D23DD23I24II24E25EE25K26KK26A27AA27S28SS28I29II29M30MM30Y31YY31P32PP32S33SS33N34NN34N35NN35C36CC36D37DD37K38KK38I39II39E40EE40V41VV41I42II42I43II43T44TT44L45LL45K46KK46E47EE47... and 26 more residue(s)...... and 26 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Structure pdb 8HNK
Ligand site mutations CXCR3


Compound is not listed as a drug.